Corrective Phases R...
Health Care: Drugs
Corcept Therapeutics Inc. (CORT: NASDAQ)
$4.08 -0.01 | -0.24%
06/01/12 - 04:00 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 0.00 | 0.00 | 29.00K | 209.00K |
| Cost of Sales | -3.00K | -6.00K | -10.00K | -12.00K |
| Gross Operating Profit | 3.00K | 6.00K | 39.00K | 221.00K |
| Selling, General, and Administrative Expenses | 11.33M | 8.49M | 5.88M | 5.75M |
| Research & Development | 21.00M | 18.95M | 14.40M | 14.15M |
| Operating Income before D & A (EBITDA) | -32.33M | -27.43M | -20.24M | -19.68M |
| Depreciation & Amortization | 3.00K | 6.00K | 10.00K | 12.00K |
| Interest Income | 3.00K | 1.50M | 101.00K | 944.00K |
| Other Income - Net | -25.00K | -25.00K | -17.00K | -1.32M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -32.35M | -25.97M | -20.17M | -20.06M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -32.35M | -25.97M | -20.17M | -20.06M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -32.35M | -25.97M | -20.17M | -20.06M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -32.35M | -25.97M | -20.17M | -20.06M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -32.35M | -25.97M | -20.17M | -20.06M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-32.35M | -25.97M | -20.17M | -20.06M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -32.35M | -25.97M | -20.17M | -20.06M |
| Basic EPS from Continuing Ops. | -0.39 | -0.38 | -0.38 | -0.43 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.39 | -0.38 | -0.38 | -0.43 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.39 | -0.38 | -0.38 | -0.43 |
| Basic Normalized Net Income/Share | -0.39 | -0.38 | -0.38 | -0.43 |
| EPS fr Continuing Ops. | -0.39 | -0.38 | -0.38 | -0.43 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.39 | -0.38 | -0.38 | -0.43 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.39 | -0.38 | -0.38 | -0.43 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.39 | -0.38 | -0.38 | -0.43 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CORT
- Portfolio NameUser Type
- Userwayne120
- Userespwes06 Portfolio 1
- ContributorStocks Under-$10 Moving Hig...
- ContributorTop 10 'Buy'-Rated Stocks U...
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- Userrubylu02
- UserBarron's Insider Purchases ...
- Usermicahw29 Portfolio 1
- Userrktjky Portfolio 1
Latest CORT Headlines from TheStreet
- Corcept Has Upside Following Drug Approval 02.21.12 | 12:02 pm
- 7 Stocks Under $10 Moving Higher 02.16.12 | 02:02 pm
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- Biotech Stock Mailbag: Corcept Therapeutics, Reader Retorts 02.10.12 | 07:02 am
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
- 27 Hot Drugs Facing FDA Approval in 2012 12.19.11 | 10:12 am
- Biotech Calendar: Key Dates for March 03.02.11 | 08:03 am
- Danver Bancorp, Dean Foods: Small-Cap Winners 01.21.11 | 01:01 pm
- Biotech Calendar: Key Dates for December 11.30.10 | 07:11 am
- Novartis Cushing's Drug Passes Late-Stage Test 09.22.10 | 07:09 am
Press Releases for CORT
Partner Headlines for CORT
- Company News for February 22, 2012 - Corporate Summary - Zacks 02.22.12 | 10:02 am
- UPDATE: Stifel Nicolaus Increases Target to $9 on Concept Therepeutics - Benzinga 02.21.12 | 09:02 am
- 12 Healthcare Companies Expecting Major February Catalysts - Seeking Alpha 02.01.12 | 07:02 am
- Upcoming PDUFA Dates for Sub-$5 Stocks - Seeking Alpha 07.05.11 | 09:07 am
- 14 Oversold Stocks With Bearish Options - Seeking Alpha 07.01.11 | 08:07 am
- 10 Undervalued Biotech Stocks With Insider Buying - Seeking Alpha 06.23.11 | 06:06 am
- 7 Small-Cap Biotechs With Bullish Insider Buying in 2011 - Seeking Alpha 06.12.11 | 05:06 am
- Low Beta Ideas: 22 High Growth, Low Beta Stocks Being Snapped Up by Mutual Funds - Seeking Alpha 06.09.11 | 09:06 am
- Upgrades, Downgrades and Initiations for Monday - Seeking Alpha 06.06.11 | 09:06 am
- UPDATE 2-Corcept hormone disorder drug meets main trial goal - Reuters 12.22.10 | 11:12 am
